Adherence to Pangenotypic Glecaprevir/Pibrentasvir Treatment and SVR12 in HCV-infected Patients: An Integrated Analysis of the Phase 2/3 Clinical Trial Program

导出原文传递

翻译打印收藏纠错

作者： Brown, Ashley S. ^[1] ; Welzel, Tania M. ^[2] ; Conway, Brian ^[3] ; Negro, Francesco ^[4] ; Brau, Norbert ^[5] ; Grebely, Jason ^[6] ; Puoti, Massimo ^[7] ; Kleine, Henning ^[8] ; Pugatch, David ^[9] ; Mensa, Federico J. ; Chen, Yaozhu J. ; Lei, Yang ; Lawitz, Eric

作者单位： James J Peters VA Med Ctr, Bronx, NY USA ^[1] UNSW Sydney, Kirby Inst, Sydney, NSW, Australia ^[2] Univ Hosp, Div Gastroenterol & Hepatol, Geneva, Switzerland ^[3] JW Goethe Univ Hosp, Frankfurt, Germany ^[4] AO Niguarda Ca Granda, Dept Infect Dis, Milan, Italy ^[5] Imperial Coll Healthcare, London, England ^[6] AbbVie, N Chicago, IL USA ^[7] Texas Liver Inst, San Antonio, TX USA ^[8] Vancouver Infect Dis Ctr, Vancouver, BC, Canada ^[9]

发布时间 2020-08-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Hepatology

2017年66卷Suppl.1期

114A-115A页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Adherence to Pangenotypic Glecaprevir/Pibrentasvir Treatment and SVR12 in HCV-infected Patients: An Integrated Analysis of the Phase 2/3 Clinical Trial Program

Hepatology

相似文献

Hepatology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Adherence to Pangenotypic Glecaprevir/Pibrentasvir Treatment and SVR12 in HCV-infected Patients: An Integrated Analysis of the Phase 2/3 Clinical Trial Program

Hepatology

相似文献

Hepatology

相关期刊

检索历史清除